References
- Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–1815.
- Hughes M, Herrick AL. Systemic sclerosis. Br J Hosp Med (Lond). 2019;80:530–536.
- Ngian GS, Sahhar J, Wicks IP, et al. Cardiovascular disease in systemic sclerosis–an emerging association? Arthritis Res Ther. 2011;13:237.
- Launay D, Sobanski V, Hachulla E, et al. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev. 2017;26:170056.
- Ichiki T, Burnett JC Jr. Atrial natriuretic peptide-old but new therapeutic in cardiovascular diseases. Circ J. 2017;81:913–919.
- Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.
- Yan W, Wu F, Morser J, et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000;97:8525–8529.
- Martinez-Rumayor A, Richards AM, Burnett JC, et al. Biology of the natriuretic peptides. Am J Cardiol. 2008;101:3–8.
- Clerico A, Vittorini S, Passino C. Circulating forms of the b-type natriuretic peptide prohormone: pathophysiologic and clinical considerations. Adv Clin Chem. 2012;58:31–44.
- Lewis RA, Durrington C, Condliffe R, et al. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? Eur Respir Rev. 2020;29:200009.
- Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146:1494–1504.
- Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340–1349.
- Kazzam E, Caidahl K, Hedner T, et al. Atrial natriuretic peptide and its relation to cardiac dimensions and function in patients with systemic sclerosis. Presse Med. 1994;23:565–570.
- Romaniello A, Rubattu S, Gigante A, et al. Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. J Cardiovasc Med (Hagerstown). 2019;20:771–779.
- Van Den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–1755.
- Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1998;15:202–205.
- Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–1285.
- Cutolo M, Sulli A, Secchi ME, et al. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology. 2006;45:43–46.
- Rudski LG, Wyman WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685–713.
- Miller MR, Crapo R, Hankinson J, et al. ATS/ERS task force. General considerations for lung function testing. Eur Respir J. 2005;26:153–161.
- Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–975.
- Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699.
- Elhai M, Meune C, Boubaya M, et al. EUSTAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897–1905.
- Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8:304–320.
- Rubattu S, Sciarretta S, Valenti V, et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am J Hypertens. 2008;21:733–741.
- Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–425.
- Baron DA, Lofton CE, Newman WH, et al. Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers. Proc Natl Acad Sci USA. 1989;86:3394–3398.
- Mitaka C, Hirata Y, Nagura T, et al. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest. 1998;114:223–228.
- Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69:1670–1678.
- Hachulla E, Clerson P, Airò P, et al. EUSTAR co-workers. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology (Oxford). 2015;54:1262–1269.